| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38c4febee9f8244d496c02490e50bad4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T137-87249
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T137-87885 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C237-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/F16K27-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C43-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C43-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C41-01 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C43-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C43-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-09 |
| filingDate |
2007-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abddd4f1360bdbad9514fab6223ba93e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_911d9685ab2ecb5b4c75b946a19a8c88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6096b3cfb1627c8b01ab51b52450acf0 |
| publicationDate |
2009-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2065358-A1 |
| titleOfInvention |
The prepartion and the use of ethoxy combretastatins and their prodrugs |
| abstract |
The invention disclosed a total synthesis process of novel ethoxy combretastatins and their prodrugs. Combretastatins are chemically modified by ethoxy substituted on the 4'-position of their B aryl ring and are converted to be their soluble prodrugs of phosphate or their inner salt of phosphorylcholine by modifying the hydroxyl on the 3'-position of their B aryl ring. Similarly, 3'-amino combretastatin is 4'-ethoxy chemically modified and further side chain of amino acid can be introduced to the amino to form soluble prodrug of amino acidamide. The structure of the said compound is showed as formula (I). Ethoxy combretastatins possess potent tubulin polymerization inhibitory activity and can be used for the treatment of inhibiting tumor or neovascular. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11254695-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2351730-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2351730-A4 |
| priorityDate |
2006-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |